stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) Return on equity
Elanco Animal Health Incorporated's return on equity over the twelve months to 30 June 2026 was −2.98%, up 0.7 percentage points from fiscal 2025 (−3.67%). Over the past ten years it has ranged from −18.2% (fiscal 2023) to 5.49% (fiscal 2024); the current reading is higher than 45% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of −0.80% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −3.67% | (9.16) |
| FY2024 | 5.49% | 23.71 |
| FY2023 | −18.2% | (17.17) |
| FY2022 | −1.05% | 4.99 |
| FY2021 | −6.04% | 2.15 |
| FY2020 | −8.19% | (9.46) |
| FY2019 | 1.27% | (0.06) |
| FY2018 | 1.33% | 5.53 |
| FY2017 | −4.20% | (3.55) |
| FY2016 | −0.65% | (0.65) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | 21.8% |
| NBIX Neurocrine Biosciences, Inc. compare | 20.4% |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 17.6% |
| RDY Dr. Reddy's Laboratories Ltd compare | 6.60% |
| ALKS Alkermes plc compare | −0.02% |
| ELAN Elanco Animal Health Incorporated | −2.98% |
| VTRS Viatris Inc. compare | −4.21% |
| HIMS Hims & Hers Health, Inc. compare | −32.0% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −53,107.2% |
| Drug Manufacturers Specialty & Generic industry median | −0.80% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ELAN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement